제일파마홀딩스, ‘한미 출신’ 김현수 상무 영입…내실 경영 드라이브

Jeil Pharma's appointment of an external pharmaceutical executive and reorganization of management support functions underscore a strategic commitment to operational efficiency and financial stability. The holding company's turnaround from years of consecutive losses to 34.6 billion won net profit in 2024 validates this management-focused strategy. This restructuring reflects the broader pharmaceutical industry trend toward strengthening governance structures and operational excellence as key drivers of sustainable profitability.